IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases. Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date.
NCI investigators at the Cancer and Inflammation Program have synthesized short peptides that selectively interfere with dimerization of the cytokines and their binding to the corresponding receptor. The peptides include metabolically stable lipopeptides mimicking conserved regions of IL-10 and IFN-gamma receptors that interfere with STAT3 and STAT1 phosphorylation and subsequent signaling. The lipopeptides strongly inhibit STAT3 and STAT1-dependent growth of cancer cells. These compounds are promising drug candidates for the treatment of cancer and many infectious and inflammatory diseases.
- Cancer, viral infections and anti-inflammatory treatments
- Dermatological treatment for psoriasis
- Rationally designed and synthesized to be potent, metabolically stable, and more therapeutic
- Highly selective IL-10 and IFN-gamma inhibitors
Nadya Tarasova (NCI), Giorgio Trinchieri (NCI), Howard Young (NCI)
Timofeeva OA, et al. [PMID: 18154267]
- U.S. Patent Filed: U.S. Patent Application Number 13/697,259, Filed 19 Dec 2012
- Foreign Filed: EP Application No. - Patent Application 11720697.9, Filed 11 May 2010